PD-L1 expressing fallopian tube carcinoma

PD-L1 expressing fallopian tube carcinoma refers to a malignant epithelial neoplasm arising from the female fallopian tube that demonstrates immunohistochemical detection of programmed death-ligand 1 (PD-L1) on tumor and/or tumor-associated immune cells Clinically grouped with epithelial ovarian and primary peritoneal cancers due to shared biology and high prevalence of high-grade serous histology, this malignancy frequently presents at advanced stages with peritoneal dissemination and ascites

PD-L1 expressing fallopian tube carcinoma refers to a malignant epithelial neoplasm arising from the female fallopian tube that demonstrates immunohistochemical detection of programmed death-ligand 1 (PD-L1) on tumor and/or tumor-associated immune cells Pathophysiologically, aberrant PD-L1 expression enables immune evasion by binding to PD-1 receptors on cytotoxic T lymphocytes, thereby inhibiting antitumor immune responses and establishing an immunosuppressive tumor microenvironment that serves...

PD-L1 expressing fallopian tube carcinoma refers to a malignant epithelial neoplasm arising from the female fallopian tube that demonstrates immunohistochemical detection of programmed death-ligand 1 (PD-L1) on tumor and/or tumor-associated immune cells Clinically grouped with epithelial ovarian and primary peritoneal cancers due to shared biology and high prevalence of high-grade serous histology, this malignancy frequently presents at advanced stages with peritoneal dissemination and ascites P...

Clinically grouped with epithelial ovarian and primary peritoneal cancers due to shared biology and high prevalence of high-grade serous histology, this malignancy frequently presents at advanced stages with peritoneal dissemination and ascites

Clinically grouped with epithelial ovarian and primary peritoneal cancers due to shared biology and high prevalence of high-grade serous histology, this malignancy frequently presents at advanced stages with peritoneal dissemination and ascites

Pathophysiologically, aberrant PD-L1 expression enables immune evasion by binding to PD-1 receptors on cytotoxic T lymphocytes, thereby inhibiting antitumor immune responses and establishing an immunosuppressive tumor microenvironment that serves as a predictive biomarker for immune checkpoint inhibitor therapy

Pathophysiologically, aberrant PD-L1 expression enables immune evasion by binding to PD-1 receptors on cytotoxic T lymphocytes, thereby inhibiting antitumor immune responses and establishing an immunosuppressive tumor microenvironment that serves as a predictive biomarker for immune checkpoint inhibitor therapy